Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Equity Ratio (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Equity Ratio for 16 consecutive years, with 0.53 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Ratio rose 8.51% year-over-year to 0.53, compared with a TTM value of 0.53 through Sep 2025, up 8.51%, and an annual FY2024 reading of 0.52, up 14.98% over the prior year.
  • Equity Ratio was 0.53 for Q3 2025 at China Pharma Holdings, up from 0.47 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.53 in Q3 2025 and bottomed at 0.17 in Q3 2022.
  • Average Equity Ratio over 5 years is 0.38, with a median of 0.38 recorded in 2021.
  • The sharpest move saw Equity Ratio crashed 53.59% in 2022, then soared 127.51% in 2023.
  • Year by year, Equity Ratio stood at 0.27 in 2021, then decreased by 9.21% to 0.24 in 2022, then skyrocketed by 87.64% to 0.45 in 2023, then grew by 14.98% to 0.52 in 2024, then increased by 1.08% to 0.53 in 2025.
  • Business Quant data shows Equity Ratio for CPHI at 0.53 in Q3 2025, 0.47 in Q2 2025, and 0.49 in Q1 2025.